Pandemic-era NIH grants (FY2019-2024) covering coronavirus, gain-of-function research, mRNA vaccines, biosafety, and related funding flows. Metadata + abstracts from NIH RePORTER.
Get an AI answer drawn only from the NIH Pandemic-Era Grants documents indexed here — every claim cited back to the filing or proceeding it came from. It will tell you plainly when the record doesn't cover your question, rather than guessing.
Robert Turner Schooley · UNIVERSITY OF CALIFORNIA, SAN DIEGO · 2021 · $169,785 — Since the emergence of SARS CoV-2 in China in the fall of 2019, nearly 200 million cases of COVID-19 have been reported globally; over 4 million of these individuals have died. In the US, the virus has been responsible for over 600,000 deaths. Despite a good understanding of non-pharmaceutical inter…
Lanying Du · GEORGIA STATE UNIVERSITY · 2021 · $554,964 — Abstract Traditional strategies of vaccine development suffer from long-term and costly manufacture, and as a result, often fail to respond rapidly to newly emerging and reemerging infectious diseases. By contrast, messenger RNA (mRNA) is rising as a new technology platform to develop vaccines “on d…
Wayne A. Marasco · DANA-FARBER CANCER INST · 2021 · $903,360 — Project Summary The emergence of the novel human betacoronavirus SARS-CoV2 in Wuhan, China in 2019 has rapidly evolved into a worldwide pandemic. Over a 100 million people have been infected and there have been several million deaths. There is also great disparity in the manner in which COVID-19 ill…
Joe H. Simmons · UNIVERSITY OF TX MD ANDERSON CAN CTR · 2021 · $499,948 — Project Summary Recent successes using nanoparticles encapsulating mRNA payload for COVID-19 vaccination have energized the field of exosomes as novel vaccine agents. Exosomes (40-180nm), extracellular vesicles of the size of a virus and shed by all cells, are actively studied in viral biology. The …
Priyamvada Acharya · DUKE UNIVERSITY · 2021 · $704,939 — Structural characterization of Fab-dimerized glycan-reactive antibodies that neutralize HIV-1 A glycan shield covers the HIV-1 envelope (Env) limiting antibody access to broadly neutralizing antibody (bnAb) epitopes. 2G12 had for long been the only example of a HIV-1 bnAb that interacts solely with…
Lanying Du · GEORGIA STATE UNIVERSITY · 2021 · $728,965 — Project Summary Viral subunit vaccines are safe and convenient, but generally suffer low efficacy. Our overall hypothesis is that an intrinsic limitation is associated with subunit vaccine designs in which artificially exposed surfaces of subunit vaccines contain epitopes unfavorable for vaccine eff…
JOHN P MOORE · WEILL MEDICAL COLL OF CORNELL UNIV · 2021 · $3,722,115 — Overall Abstract This HIVRAD Program Project renewal application is made in response to PAR-18-319. It contains two Research Projects, one Scientific Core and an Administrative Core, under the direction of Principal Investigator, John P. Moore, PhD (Weill Cornell Medical College; WCMC) and co-Princi…
Mahesh B Chandrasekharan · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · 2021 · $228,750 — Project summary: ChIP-seq has enabled the mapping of genomic occupancy of many chromatin factors and epigenetic histone modifications, linked to normal growth and development and to the pathogenesis of many human diseases. ChIP-seq can also measure changes in the occupancy levels of epigenomic marks…
Graham Thomas Dempsey · Q-STATE BIOSCIENCES, INC. · 2021 · $713,034 — Project Summary: Synaptic dysfunction has been implicated in many neurological diseases including epilepsy, Alzheimer’s, Parkinson’s, autism spectrum disorder (ASD), schizophrenia, depression, ADHD and Huntington’s. Despite the prevalence and severity of these disorders, the development of new thera…
Rebecca Michelle DuBois · UNIVERSITY OF CALIFORNIA SANTA CRUZ · 2021 · $73,446 — PROJECT SUMMARY Human astroviruses (HAstV) are a leading cause of viral diarrhea in children. Divergent HAstV strains are associated with fatal human encephalitis. Currently, no vaccines or antiviral therapies exist for HAstV infections. Our goal is to identify sites of vulnerability (Achilles' heel…
STEPHEN COPLAN HARRISON · BOSTON CHILDREN'S HOSPITAL · 2021 · $420,375 — Summary The structure of a virus particle must conform to the mechanism by which it enters and infects a cell. We seek to relate structures of virus particles and viral surface proteins to mechanisms of the steps in cell attachment, uptake and penetration that initiate a productive infection. The pr…
Rebecca Michelle DuBois · UNIVERSITY OF CALIFORNIA SANTA CRUZ · 2021 · $350,421 — PROJECT SUMMARY Human astroviruses (HAstV) are a leading cause of viral diarrhea in children. Divergent HAstV strains are associated with fatal human encephalitis. Currently, no vaccines or antiviral therapies exist for HAstV infections. Our goal is to identify sites of vulnerability (Achilles' heel…
Robert N Kirchdoerfer · UNIVERSITY OF WISCONSIN-MADISON · 2021 · $248,994 — SUMMARY Coronaviruses are sporadically emerging viruses responsible for SARS and MERS disease outbreaks. There are currently no direct treatments for these viruses, nor is there a vaccine which induces broad protection from infection. However, several stages in the virus life cycle are promising ta…
Lanying Du · NEW YORK BLOOD CENTER · 2021 · $339,869 — Abstract Traditional strategies of vaccine development suffer from long-term and costly manufacture, and as a result, often fail to respond rapidly to newly emerging and reemerging infectious diseases. By contrast, messenger RNA (mRNA) is rising as a new technology platform to develop vaccines “on d…
Matthew Reed Steinhart · INDIANA UNIVERSITY INDIANAPOLIS · 2021 · $37,679 — ABSTRACT Neurofibromatosis Type 2 (NF2) is a genetic condition in which specific types of tumors form in various locations throughout the body. Though the majority of these tumors grow slowly, the location of certain tumors can cause significant dysfunction. One of these tumor types grows on the ves…
ANDRE ANTONIO FENTON · NEW YORK UNIVERSITY · 2021 · $343,384 — ABSTRACT Full mutation of the FMR1 gene causes loss of the fragile X mental retardation protein (FMRP) and fragile X syndrome (FXS) characterized by intellectual disability with devastating cognitive consequences and features of autism. Study of Fmr1 knockout (KO) mouse models of the FXS genetic def…
Naoko Mizuno · NATIONAL HEART, LUNG, AND BLOOD INSTITUTE · 2021 · $382,608 — Using live imaging and cellular cryo-electron tomography (cryo-ET) techniques, we obtained results showing that platelets are directly activated in the presence of purified SARS-Cov2 spike protein. We have optimized conditions to embed platelets onto EM grids and we are currently observing activated…
Andrea Marzi · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · 2021 · $38,451 — The lab developed 2 vaccine candidates expressing the SARS-CoV-2 spike protein alone or in combination with the Ebola virus glycoprotein (EBOV GP). Hamster studies revealed that a single dose of either vaccine administered intranasally (IN) or intramuscularly (IM) protected the animals from disease …
Joshua Hoong Yu Tan · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · 2021 · $143,050 — The overarching goal of this project is to study the immune response to COVID-19 at the monoclonal level to increase our understanding of basic biology and develop new tools to combat disease. We have screened plasma from >100 acutely infected and convalescent COVID-19 individuals for neutralization…
JOSHUA ZIMMERBERG · EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT · 2021 · $3,483,111 — 1. To combat COVID-19, high throughput screening (HTS) of thousands of candidate compounds that may block or reduce SARS-CoV-2 infection of target tissues is a powerful tool in drug discovery. However, SARS-CoV-2 is a biological safety level 3 (BSL-3) pathogen and most HTS facilities are only BSL-2.…